OTIS
Otis Worldwide Corporation
OTIS has the edge over RKLB overall, supported by lower modeled downside and stronger valuation.
RKLB
Rocket Lab USA, Inc.
RKLB offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
OTIS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
OTIS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
RKLB Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Weak | |
| Unavailable |
RKLB's revenue is currently strong, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
OTIS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $77.14 | — |
| Current | 19x | $77.14 | — |
| Cheap | 23x | $94.13 | +22% |
| Fair | 27x | $107 | +39% |
| Expensive | 30x | $122 | +58% |
Historical ranges are pointers, not guarantees.
OTIS's PE is in its cheap range at 19x. If earnings grow as analysts expect, today's price would be 18x next year's earnings.
RKLB PE Valuation
RKLB has no meaningful PE right now: it lost money over the past year.
OTIS Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect OTIS's earnings to grow and its profitability to improve, with its revenue holding steady.
RKLB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Low |
RKLB has the edge over OTIS on the outlook, with more favorable revenue expectations.
OTIS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $4.37 | +8.7% |
| Q3 2026 | $4.02 | +18% |
| Q2 2026 | $3.89 | +2.6% |
| Q1 2026 | $3.76 | -1.6% |
| Q4 2025 | $3.50 | -14% |
| Q3 2025 | $3.40 | -15% |
| Q2 2025 | $3.79 | +5.9% |
| Q1 2025 | $3.82 | +10% |
| Q4 2024 | $4.07 | +20% |
OTIS has the edge over RKLB on earnings quality, reporting a profit while its opponent remains loss making.
RKLB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.36 | +$0.03 |
| Q2 2026 | -$0.27 | +$0.19 |
| Q1 2026 | -$0.32 | +$0.09 |
| Q4 2025 | -$0.37 | +$0.01 |
| Q3 2025 | -$0.39 | -$0.02 |
| Q2 2025 | -$0.46 | -$0.11 |
| Q1 2025 | -$0.41 | -$0.04 |
| Q4 2024 | -$0.38 | $0.00 |
RKLB is still losing money, but less than at its worst: $0.36 per share over the past year, against $0.46 at its worst in mid-2025.
OTIS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $3.9B | +6.1% |
| Q2 2026 | $3.9B | +7.3% |
| Q1 2026 | $3.6B | +6.4% |
| Q4 2025 | $3.8B | +3.3% |
| Q3 2025 | $3.7B | +4% |
| Q2 2025 | $3.6B | -0.2% |
| Q1 2025 | $3.4B | -2.5% |
| Q4 2024 | $3.7B | +1.5% |
OTIS's revenue has grown year over year for five quarters in a row: $3.9B last quarter, up 6.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 16% | 0 points |
| Q2 2026 | 15% | -0.3 points |
| Q1 2026 | 15% | +2.8 points |
| Q4 2025 | 16% | +1.1 points |
| Q3 2025 | 16% | +5.7 points |
| Q2 2025 | 15% | -0.6 points |
| Q1 2025 | 12% | -3.6 points |
| Q4 2024 | 14% | 0 points |
OTIS has the edge over RKLB on profitability, with a higher operating margin.
RKLB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $267.8M | +73% |
| Q2 2026 | $234.1M | +62% |
| Q1 2026 | $200.3M | +63% |
| Q4 2025 | $179.7M | +36% |
| Q3 2025 | $155.1M | +48% |
| Q2 2025 | $144.5M | +36% |
| Q1 2025 | $122.6M | +32% |
| Q4 2024 | $132.4M | +121% |
RKLB has the edge over OTIS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -30% | +8.5 points |
| Q2 2026 | -25% | +17 points |
| Q1 2026 | -28% | +20 points |
| Q4 2025 | -28% | +11 points |
| Q3 2025 | -38% | +12 points |
| Q2 2025 | -41% | -0.5 points |
| Q1 2025 | -48% | -1.9 points |
| Q4 2024 | -39% | +41 points |
RKLB's operating margin was −30% last quarter, up 8.5 points from the same quarter a year ago.
OTIS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $298M | -12% |
| Q2 2026 | $223M | +25% |
| Q1 2026 | $380M | +144% |
| Q4 2025 | $772M | +19% |
| Q3 2025 | $337M | -6.9% |
| Q2 2025 | $179M | -37% |
| Q1 2025 | $156M | +11% |
| Q4 2024 | $651M | +17% |
OTIS has the edge over RKLB on cash generation, producing positive trailing cash flow while its opponent burns cash.
RKLB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$23.9M | +$45.5M |
| Q2 2026 | -$110.1M | -$54.8M |
| Q1 2026 | -$77.4M | +$5.5M |
| Q4 2025 | -$114.2M | -$90.2M |
| Q3 2025 | -$69.4M | -$27.5M |
| Q2 2025 | -$55.3M | -$26.9M |
| Q1 2025 | -$82.9M | -$61.1M |
| Q4 2024 | -$23.9M | +$28.7M |
RKLB has burned cash in almost every quarter: −$326M over the past year, against −$232M the year before.
OTIS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.6M shares |
| 1 year | -2.8% | -10.9M shares |
| 3 years | -7.7% | -31.8M shares |
| 5 years | -11% | -48.7M shares |
| Available history | -12% | -51.2M shares |
OTIS has the edge over RKLB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | $407M |
| Q1 2026 | $400M |
| Q4 2025 | — |
| Q3 2025 | $248M |
| Q2 2025 | $308M |
| Q1 2025 | $253M |
| Q4 2024 | $207M |
OTIS spent $807M buying back its own shares over the past year, down 21% from the year before.
RKLB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.6% | +22.6M shares |
| 1 year | +23% | +124M shares |
| 3 years | +35% | +168M shares |
| 5 years | +46% | +204M shares |
RKLB has 652M diluted shares, up 23% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
OTIS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Moderate |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 2.9x | Moderate |
| Q4 2025 | 3.0x | Moderate |
| Q3 2025 | 3.2x | Elevated |
| Q2 2025 | 3.5x | Elevated |
| Q1 2025 | 3.2x | Elevated |
| Q4 2024 | 2.8x | Moderate |
OTIS's net debt is about 3.0 years of its operating earnings (EBITDA), down from 3.2 years a year ago.
RKLB Net Leverage
RKLB's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
OTIS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.8 | Neutral |
| Stochastic | 86.8 | Overbought |
OTIS's weekly RSI is 57 (neutral) and its Stochastic is 87 (overbought).
RKLB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 46.8 | Neutral |
| Stochastic | 27.6 | Neutral |
RKLB's weekly RSI is 47 (neutral) and its Stochastic is 28 (neutral).
OTIS PE vs Industrials Sector
| Metric | OTIS | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 24x | 20% below |
| PE % | 6 | 57 | 51 pts below |
OTIS is trading at 19x earnings, a 20% discount to the Industrials sector's median of 24x.
RKLB PE vs Industrials Sector
RKLB has no meaningful PE right now: it lost money over the past year.
OTIS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $71.8 | 7.5% above |
| 20 week MA | $71.8 | 7.4% above |
| 50 week MA | $77.9 | 1% below |
| 100 week MA | $86.0 | 10% below |
| 200 week MA | $88.1 | 12% below |
OTIS has bounced recently, but its long-term trend is still down: it's above its 8- and 20-week averages, but 12% below its 200-week average.
RKLB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $61.4 | 4.3% above |
| 20 week MA | $68.1 | 5.9% below |
| 50 week MA | $77.6 | 17% below |
| 100 week MA | $56.5 | 13% above |
| 200 week MA | $31.4 | 104% above |
RKLB has the edge over OTIS on trend strength, trading above more of its moving averages.
OTIS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $45.0 | $65.8 | +46% |
| 2021 | $65.8 | $85.3 | +30% |
| 2022 | $85.3 | $78.4 | -8.1% |
| 2023 | $78.4 | $89.5 | +14% |
| 2024 | $89.5 | $93.5 | +4.5% |
| 2025 | $93.5 | $87.6 | -6.3% |
| 2026 YTD | $87.6 | $77.1 | -12% |
OTIS has finished higher in four of the last six years. It's down 12% so far in 2026.
RKLB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.82 | $10.3 | +4.9% |
| 2021 | $10.3 | $12.0 | +17% |
| 2022 | $12.0 | $3.77 | -69% |
| 2023 | $3.77 | $5.53 | +47% |
| 2024 | $5.53 | $27.2 | +392% |
| 2025 | $27.2 | $70.7 | +160% |
| 2026 YTD | $70.7 | $64.1 | -9.3% |
RKLB has the edge over OTIS on returns for 2026, with the stronger performance.